NewAmsterdam Pharma Investor Day Focuses on PREVAIL, Alzheimer's

NewAmsterdam Pharma (NAMS) held its annual investor day on Aug. 5, with management presenting updates on two key pipeline programs: the PREVAIL cardiovascular outcomes trial and the company's Alzheimer's disease program.

Chief Executive Michael Davidson gave a corporate update, followed by Chief Scientific Officer John Kastelein on the science. Chief Commercial Officer BJ Jones covered the commercial strategy. Chief Financial Officer Mayur Somaiya took questions after the presentations.

Analysts from TD Cowen, Cantor Fitzgerald, RBC Capital Markets, Leerink Partners, William Blair, Truist Securities and Wells Fargo attended the session.

The company did not disclose any new data during the introductory portion. No timeline for PREVAIL data was provided.